|Indication|| ‒ Healing of all grades of erosive esophagitis (EE)
‒ Maintaining healing of EE
‒ Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD)
|Status|| ‒ The commercialization partner, Par, received final approval in April 2017.
‒ US Launched in November 2022 by Par Pharmaceutical.
|Product Advantages|| ‒ Settled with the brand company.
‒ Final approval for 30mg and 60mg.
|Market Size||According to IQVIA data, the total sales of Dexlansoprazole DR Capsule in the US were approximately US$0.453 billion for the first half of 2022.|